Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

NCT07410234 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Toripalimab
RADIATION: SBRT
DRUG: standard neoadjuvant chemotherapy regimens

Sponsor

Tianjin Medical University Cancer Institute and Hospital